|
1
|
Hsueh EC and Gorantla KC: Novel melanoma
therapy. Exp Hematol Oncol. 5:232016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
La Porta CA: Mechanism of drug sensitivity
and resistance in melanoma. Curr Cancer Drug Targets. 9:391–397.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kuphal S and Bosserhoff A: Recent progress
in understanding the pathology of malignant melanoma. J Pathol.
219:400–409. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nazarian R, Shi H, Wang Q, Kong X, Koya
RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, et al: Melanomas
acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS
upregulation. Nature. 468:973–977. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD-1 blockade in melanoma. N
Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Larkin J, Chmielowski B, Lao CD, Hodi FS,
Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D,
et al: Neurologic serious adverse events associated with nivolumab
plus ipilimumab or nivolumab alone in advanced melanoma, including
a case series of encephalitis. Oncologist. 22:709–718. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Long GV, Atkinson V, Cebon JS, Jameson MB,
Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA,
et al: Standard-dose pembrolizumab in combination with reduced-dose
ipilimumab for patients with advanced melanoma (KEYNOTE-029): An
open-label, phase 1b trial. Lancet Oncol. 18:1202–1210. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Melis C, Rogiers A, Bechter O and van den
Oord JJ: Molecular genetic and immunotherapeutic targets in
metastatic melanoma. Virchows Arch. 471:281–293. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Son B, Lee S, Youn H, Kim E, Kim W and
Youn B: The role of tumor microenvironment in therapeutic
resistance. Oncotarget. 8:3933–3945. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang T, Xiao M, Ge Y, Krepler C, Belser E,
Lopez-Coral A, Xu X, Zhang G, Azuma R, Liu Q, et al: BRAF
inhibition stimulates melanoma-associated macrophages to drive
tumor growth. Clin Cancer Res. 21:1652–1664. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smith BD, Kaufman MD, Leary CB, Turner BA,
Wise SC, Ahn YM, Booth RJ, Caldwell TM, Ensinger CL, Hood MM, et
al: Altiratinib inhibits tumor growth, invasion, angiogenesis, and
microenvironment-mediated drug resistance via balanced inhibition
of MET, TIE2, and VEGFR2. Mol Cancer Ther. 14:2023–2034. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Castells M, Thibault B, Delord JP and
Couderc B: Implication of tumor microenvironment in
chemoresistance: Tumor-associated stromal cells protect tumor cells
from cell death. Int J Mol Sci. 13:9545–9571. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Affara NI, Ruffell B, Medler TR, Gunderson
AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong
Q, et al: B cells regulate macrophage phenotype and response to
chemotherapy in squamous carcinomas. Cancer Cell. 25:809–821. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ries CH, Cannarile MA, Hoves S, Benz J,
Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I,
et al: Targeting tumor-associated macrophages with anti-CSF-1R
antibody reveals a strategy for cancer therapy. Cancer Cell.
25:846–859. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Solinas G, Germano G, Mantovani A and
Allavena P: Tumor-associated macrophages (TAM) as major players of
the cancer-related inflammation. J Leukoc Biol. 86:1065–1073. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mantovani A, Sozzani S, Locati M, Allavena
P and Sica A: Macrophage polarization: Tumor-associated macrophages
as a paradigm for polarized M2 mononuclear phagocytes. Trends
Immunol. 23:549–555. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tham M, Tan KW, Keeble J, Wang X, Hubert
S, Barron L, Tan NS, Kato M, Prevost-Blondel A, Angeli V and
Abastado JP: Melanoma-initiating cells exploit M2 macrophage
TGFbeta and arginase pathway for survival and proliferation.
Oncotarget. 5:12027–12042. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yaddanapudi K, Putty K, Rendon BE, Lamont
GJ, Faughn JD, Satoskar A, Lasnik A, Eaton JW and Mitchell RA:
Control of tumor-associated macrophage alternative activation by
macrophage migration inhibitory factor. J Immunol. 190:2984–2993.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Clear AJ, Lee AM, Calaminici M, Ramsay AG,
Morris KJ, Hallam S, Kelly G, Macdougall F, Lister TA and Gribben
JG: Increased angiogenic sprouting in poor prognosis FL is
associated with elevated numbers of CD163+ macrophages
within the immediate sprouting microenvironment. Blood.
115:5053–5056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Leek RD, Lewis CE, Whitehouse R, Greenall
M, Clarke J and Harris AL: Association of macrophage infiltration
with angiogenesis and prognosis in invasive breast carcinoma.
Cancer Res. 56:4625–4629. 1996.PubMed/NCBI
|
|
22
|
Liu T, Larionova I, Litviakov N, Riabov V,
Zavyalova M, Tsyganov M, Buldakov M, Song B, Moganti K, Kazantseva
P, et al: Tumor-associated macrophages in human breast cancer
produce new monocyte attracting and pro-angiogenic factor YKL-39
indicative for increased metastasis after neoadjuvant chemotherapy.
Oncoimmunology. 7:e14369222018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shieh YS, Hung YJ, Hsieh CB, Chen JS, Chou
KC and Liu SY: Tumor-associated macrophage correlated with
angiogenesis and progression of mucoepidermoid carcinoma of
salivary glands. Ann Surg Oncol. 16:751–760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marech I, Ammendola M, Sacco R, Sammarco
G, Zuccalà V, Zizzo N, Leporini C, Luposella M, Patruno R,
Filippelli G, et al: Tumour-associated macrophages correlate with
microvascular bed extension in colorectal cancer patients. J Cell
Mol Med. 20:1373–1380. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Alupei MC, Licarete E, Patras L and Banciu
M: Liposomal simvastatin inhibits tumor growth via targeting
tumor-associated macrophages-mediated oxidative stress. Cancer
Lett. 356:946–952. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Banciu M, Metselaar JM, Schiffelers RM and
Storm G: Antitumor activity of liposomal prednisolone phosphate
depends on the presence of functional tumor-associated macrophages
in tumor tissue. Neoplasia. 10:108–117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Banciu M, Schiffelers RM and Storm G:
Investigation into the role of tumor-associated macrophages in the
antitumor activity of Doxil. Pharm Res. 25:1948–1955. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sylvester B, Porfire A, Muntean DM, Vlase
L, Lupuţ L, Licarete E, Sesarman A, Alupei MC, Banciu M, Achim M
and Tomuţă I: Optimization of prednisolone-loaded long-circulating
liposomes via application of quality by design (QbD) approach. J
Liposome Res. 28:49–61. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
De Palma M and Lewis CE: Macrophage
regulation of tumor responses to anticancer therapies. Cancer Cell.
23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cortes-Funes H and Coronado C: Role of
anthracyclines in the era of targeted therapy. Cardiovasc Toxicol.
7:56–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fink W, Zimpfer-Rechner C, Thoelke A, Figl
R, Kaatz M, Ugurel S and Schadendorf D: Clinical phase II study of
pegylated liposomal doxorubicin as second-line treatment in
disseminated melanoma. Onkologie. 27:540–544. 2004.PubMed/NCBI
|
|
32
|
Schadendorf D, Worm M, Algermissen B,
Kohlmus CM and Czarnetzki BM: Chemosensitivity testing of human
malignant melanoma. A retrospective analysis of clinical response
and in vitro drug sensitivity. Cancer. 73:103–108. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Vorobiof DA, Rapoport BL, Mahomed R and
Karime M: Phase II study of pegylated liposomal doxorubicin in
patients with metastatic malignant melanoma failing standard
chemotherapy treatment. Melanoma Res. 13:201–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Haase-Kohn C, Wolf S, Herwig N, Mosch B
and Pietzsch J: Metastatic potential of B16-F10 melanoma cells is
enhanced by extracellular S100A4 derived from RAW264.7 macrophages.
Biochem Biophys Res Commun. 446:143–148. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang X, Goncalves R and Mosser DM: The
isolation and characterization of murine macrophages. Curr Protoc
Immunol. 14:Unit 14 11. 2008. View Article : Google Scholar
|
|
36
|
Rauca VF, Licarete E, Luput L, Sesarman A,
Patras L, Bulzu P, Rakosy-Tican E and Banciu M: Combination therapy
of simvastatin and 5,6-dimethylxanthenone-4-acetic acid
synergistically suppresses the aggressiveness of B16.F10 melanoma
cells. PLoS One. 13:e02028272018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Banciu M, Fens MH, Storm G and Schiffelers
RM: Antitumor activity and tumor localization of liposomal
glucocorticoids in B16 melanoma-bearing mice. J Control Release.
127:131–136. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Licarete E, Sesarman A, Rauca VF, Luput L,
Patras L and Banciu M: HIF-1α acts as a molecular target for
simvastatin cytotoxicity in B16.F10 melanoma cells cultured under
chemically induced hypoxia. Oncol Lett. 13:3942–3950. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Alupei MC, Licarete E, Cristian FB and
Banciu M: Cytotoxicity of lipophilic statins depends on their
combined actions on HIF-1α expression and redox status in B16.F10
melanoma cells. Anticancer Drugs. 25:393–405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Karatas F, Karatepe M and Baysar A:
Determination of free malondialdehyde in human serum by
high-performance liquid chromatography. Anal Biochem. 311:76–79.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chou TC and Talalay P: Quantitative
analysis of dose-effect relationships: The combined effects of
multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 22:27–55.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Venza M, Visalli M, Beninati C, De Gaetano
GV, Teti D and Venza I: Cellular mechanisms of oxidative stress and
action in melanoma. Oxid Med Cell Longev. 2015:4817822015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Rőszer T: Understanding the mysterious M2
macrophage through activation markers and effector mechanisms.
Mediators Inflamm. 2015:8164602015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Larionova I, Cherdyntseva N, Liu T,
Patysheva M, Rakina M and Kzhyshkowska J: Interaction of
tumor-associated macrophages and cancer chemotherapy.
Oncoimmunology. 8:15960042019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Manzano JL, Layos L, Bugés C, de Los
Llanos Gil M, Vila L, Martínez-Balibrea E and Martínez-Cardús A:
Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl
Med. 4:2372016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Winder M and Viros A: Mechanisms of drug
resistance in melanoma. Handb Exp Pharmacol. 249:91–108. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Vera RE, Lamberti MJ, Rivarola VA and
Rumie Vittar NB: Developing strategies to predict photodynamic
therapy outcome: The role of melanoma microenvironment. Tumour
Biol. 36:9127–9136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Klemm F and Joyce JA: Microenvironmental
regulation of therapeutic response in cancer. Trends Cell Biol.
25:198–213. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Szebeni GJ, Vizler C, Kitajka K and Puskas
LG: Inflammation and cancer: Extra- and intracellular determinants
of tumor-associated macrophages as tumor promoters. Mediators
Inflamm. 2017:92940182017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gajewski TF: Identifying and overcoming
immune resistance mechanisms in the melanoma tumor
microenvironment. Clin Cancer Res. 12:2326s–2330s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Varney ML, Olsen KJ, Mosley RL and Singh
RK: Paracrine regulation of vascular endothelial growth factor-a
expression during macrophage-melanoma cell interaction: Role of
monocyte chemotactic protein-1 and macrophage colony-stimulating
factor. J Interferon Cytokine Res. 25:674–683. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma
R, Somasundaram R, Zhang G, Wei Z, Xu X, Rauscher FJ III, et al:
Melanoma-derived conditioned media efficiently induce the
differentiation of monocytes to macrophages that display a highly
invasive gene signature. Pigment Cell Melanoma Res. 25:493–505.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ruffell B and Coussens LM: Macrophages and
therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Banciu M, Metselaar JM, Schiffelers RM and
Storm G: Liposomal glucocorticoids as tumor-targeted
anti-angiogenic nanomedicine in B16 melanoma-bearing mice. J
Steroid Biochem Mol Biol. 111:101–110. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Gouaze V, Mirault ME, Carpentier S,
Salvayre R, Levade T and Andrieu-Abadie N: Glutathione peroxidase-1
overexpression prevents ceramide production and partially inhibits
apoptosis in doxorubicin-treated human breast carcinoma cells. Mol
Pharmacol. 60:488–496. 2001.PubMed/NCBI
|
|
58
|
Ubezio P and Civoli F: Flow cytometric
detection of hydrogen peroxide production induced by doxorubicin in
cancer cells. Free Radic Biol Med. 16:509–516. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Berthiaume JM and Wallace KB:
Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell
Biol Toxicol. 23:15–25. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wang S, Konorev EA, Kotamraju S, Joseph J,
Kalivendi S and Kalyanaraman B: Doxorubicin induces apoptosis in
normal and tumor cells via distinctly different mechanisms.
Intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem.
279:25535–25543. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Verma N and Vinayak M: A low dose of
doxorubicin improves antioxidant defence system and modulates
anaerobic metabolism during the development of lymphoma. Indian J
Pharmacol. 44:308–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pritsos CA and Ma J: Basal and
drug-induced antioxidant enzyme activities correlate with
age-dependent doxorubicin oxidative toxicity. Chem Biol Interact.
127:1–11. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dong QM, Ling C, Chen X and Zhao LI:
Inhibition of tumor necrosis factor-α enhances apoptosis induced by
nuclear factor-kB inhibition in leukemia cells. Oncol Lett.
10:3793–3798. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kirito K, Watanabe T, Sawada K, Endo H,
Ozawa K and Komatsu N: Thrombopoietin regulates Bcl-xL gene
expression through Stat5 and phosphatidylinositol 3-kinase
activation pathways. J Biol Chem. 277:8329–8337. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Nalluri S, Ghoshal-Gupta S, Kutiyanawalla
A, Gayatri S, Lee BR, Jiwani S, Rojiani AM and Rojiani MV: TIMP-1
inhibits apoptosis in lung adenocarcinoma cells via interaction
with Bcl-2. PLoS One. 10:e01376732015. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Valacca C, Tassone E and Mignatti P:
TIMP-2 interaction with MT1-MMP activates the AKT pathway and
protects tumor cells from apoptosis. PLoS One. 10:e01367972015.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Valente P, Fassina G, Melchiori A,
Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson
WG and Albini A: TIMP-2 over-expression reduces invasion and
angiogenesis and protects B16F10 melanoma cells from apoptosis. Int
J Cancer. 75:246–253. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Georgoudaki AM, Prokopec KE, Boura VF,
Hellqvist E, Sohn S, Östling J, Dahan R, Harris RA, Rantalainen M,
Klevebring D, et al: Reprogramming tumor-associated macrophages by
antibody targeting inhibits cancer progression and metastasis. Cell
Rep. 15:2000–2011. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Zheng X, Turkowski K, Mora J, Brüne B,
Seeger W, Weigert A and Savai R: Redirecting tumor-associated
macrophages to become tumoricidal effectors as a novel strategy for
cancer therapy. Oncotarget. 8:48436–48452. 2017.PubMed/NCBI
|
